Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

NCT00766337 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: Sirolimus in combination with ranibizumab
DRUG: Sirolimus in combination with ranibizumab
DRUG: Placebo in combination with ranibizumab

Sponsor

Santen Inc.

Collaborators

[object Object]